C
rohn's disease (CD) is an idiopathic, chronic inflammatory disorder affecting the gastrointestinal tract characterized by transmural inflammation that can lead to severe complications, including intestinal strictures, fistulae, and abscesses. The hallmark histologic feature of CD described in the original paper by Crohn et al 1 is the epithelioid granuloma, although this finding is present only in a subset of patients. The granuloma is a localized collection of inflammatory cells including macrophages and T lymphocytes associated with cytokines, including interleukin-12, -17, -23, interferon-g, and tumor necrosis factor (TNF)-a, which physiologically functions to protect against disseminated infection with mycobacteria and fungal organisms. However, the role of the granuloma in the pathogenesis of CD is unclear.
The first study to examine the relationship between the presence of granuloma and disease behavior in CD was conducted in 1960, 2 and multiple studies over the past several decades have yielded conflicting results in regard to this issue. [3] [4] [5] [6] [7] [8] [9] [10] Granuloma formation depends on type-1 inflammatory cytokines and TNF-a, produced in large part by macrophages. The importance of TNF-a for granuloma formation is evidenced by the ability of the TNF-blocking biologic agents to cause reactivation of tuberculosis and certain fungal infections. Anti-TNF biologics are thought to disrupt granuloma formation by different mechanisms, including neutralization of soluble TNF and inducing macrophage cell death by apoptosis or by complement fixation. 11 The effect of anti-TNF biologics on granuloma rates in patients with CD has, to our knowledge, been examined in only one study. 12 In this study from 2014, anti-TNF exposure correlated with reduced rates of granulomas in resection specimens.
At present, there are no histologic biomarkers that have demonstrated prognostic significance to guide clinical decision making in CD. In this study, we sought to investigate the possible predictive role of the presence of epithelioid granulomas in relation to disease severity characterized by multiyear well-defined disease characteristics in a large cohort of patients with CD. An additional aim was the investigation of the treatment effect of anti-TNF biologic agents on granuloma detection in CD.
Methods
The Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center maintains a prospective natural history registry that tracks more than 3000 consented patients and has been described in detail. 13 Specific data are collected at the time of office encounters regarding disease activity (Harvey Bradshaw Index [HBI] ) and behavior, quality of life (Short Inflammatory Bowel Disease Questionnaire), medication use, and health care use. Unless otherwise noted, medication use was defined as having at least one prescription for the drug in question during the study period. Likewise, patients were classified as having an abnormal laboratory value if there was at least one abnormal value recorded during the study period (ie, elevated C-reactive protein [CRP] , elevated erythrocyte sedimentation rate [ESR] ).
The entire cohort and the subset of patients undergoing surgical resection were analyzed separately with regard to granuloma rates. Patients were divided into two groups: no granuloma and granuloma based on review of surgical pathology reports on both biopsies and surgical specimens. This was accomplished by text search using the term "granuloma" followed by manual review and confirmation of each report identified as containing granulomas. These specimens were evaluated by a gastrointestinal pathology subspecialty center of excellence. A subset of the overall cohort consisting of surgical resection specimens was reviewed by a subspecialized gastrointestinal pathologist and the locations of the granulomas were assessed. Each specimen classified as granulomatous contained at least one nonnecrotizing, epithelioid granuloma. Specimens containing only granulomas associated with crypt rupture or foreign body (food material or suture material) granulomas were classified as nongranulomatous for the purposes of this analysis. In each case, appropriate stains were performed to rule out both mycobacterial and fungal infection, and specimens deemed to have granulomas of infectious origin were excluded from this study. Patients were placed in the granuloma group if at least one of their available pathology specimens was classified as granulomatous.
The Lémann index is a measure of cumulative bowel damage in patients with CD, 14 and the delta Lémann index (DLI) is a recently developed measure of disease trajectory. 15 The DLI was calculated in a subset of study patients for whom more than one endoscopic evaluation was available. The patients were categorized as having improving bowel damage (DLI <0), stable bowel damage (DLI ¼ 0), or worsening bowel damage (DLI >0), and the rates of granuloma in each group were compared. To determine which patients were on an anti-TNF drug at the time of surgical resection, the authors identified patients with an anti-TNF prescription during the year of the surgery. Of this group, each patient's chart was then reviewed to confirm that they were in fact taking the anti-TNF up until surgery.
Statistical Analysis
Data were analyzed using SPSS Statistics version 23 (Armonk, NY). Data were tested for centrality using the Kolmogorov-Smirnov/Lilliefors test. Data sets that satisfied normality were expressed as the mean AE standard deviation. Data sets that were nonnormally distributed were expressed as median with interquartile range. Differences between groups were evaluated using the Mann-Whitney U test for continuous variables, and chi-square or Fisher exact test for categorical variables. Variables that were statistically different in univariate analysis were included in a multivariate logistic regression model to test which variables were independently associated with the presence of granulomas.
Ethical Considerations
The University of Pittsburgh's Institutional Review Board approved enrollment and participation of subjects in this study (PRO12110117).
Results

Baseline Characteristics of the Crohn's Disease Study Population
There were 1466 patients with CD with histologic material available who formed the study population (Table 1) . Mean follow up of these patients was 4.5 (AE 2.2) years during the 6-year observation period with no significant difference between the two study groups (4.6 years for nongranuloma, and 4.2 years for granuloma patients). Eight hundred (54.6%) patients were female, the mean age at time of diagnosis was 27.4 years, and 1371 (93.5%) were non-Hispanic white. Six hundred and twenty-two (42.8%) were characterized as smokers, defined as either active smoking or having a prior history of smoking. Rates of medication use (prednisone, immunomodulators, biologics, narcotics), laboratory data (CRP, ESR), clinical activity (HBI), quality of life scores (Short Inflammatory Bowel Disease Questionnaire), and health care use data for the study population are listed in Table 1 . Anatomic and histologic locations of granulomas were also noted (Supplementary Table 2 ).
Comparison of Patients With Crohn's Disease With and Without Granulomas
Overall, 187 patients (12.8%) were identified as having granulomatous CD. Among the granuloma patients, 109 (58.3%) were female compared with 691 (54%) in the no-granuloma group (P ¼ .27). The granuloma patients were diagnosed at a younger mean age (P ¼ .0005). There were no statistically significant associations between race or smoking and granuloma rates (for smoking, P ¼ .86; granuloma rates by race are summarized in Table 1 ). Mean prednisone exposure, defined as the mean number of years during the study period in which at least one prednisone prescription was written, was higher in the granuloma group (1.73 vs 1.08 years; P < .0001). Likewise, patients in the granuloma group were more likely to have been prescribed immunomodulators (78.1% vs 49.1%), biologics (60.4% vs 41.8%), and narcotics (49.2% vs 34.8%) during the study period. P values for these comparisons were all <.001. The association between various laboratory abnormalities and granulomatous CD was also examined. Patients with granulomatous CD were more likely to have at least one abnormal CRP (73.2% vs 48.0%) or ESR (58.1% vs 35.1%) value (both P < .0001). Granulomatous CD was associated with higher mean HBI scores (5.24 vs 4.36; P ¼ .02), and lower Short Inflammatory Bowel Disease Questionnaire scores (47.2 vs 49.5; P ¼ .03). Finally, mean hospitalizations per year (0.49 vs 0.25) and mean emergency department visits per year (0.60 vs 0.38) were significantly higher in the granulomatous CD group (both P < .0001). Because the frequency of granulomas may directly correlate with the number of biopsy specimens taken per procedure, we compared the mean number of endoscopic biopsies per procedure in the granuloma and no-granuloma groups (Supplementary Table 1) . Results showed no significant difference in the mean number of biopsies per procedure between the two groups (11.6 vs 10.0; P ¼ .196). Anatomic locations of granulomas were also noted (Supplementary Table 2 ). Calculated as mean number of years with a steroid prescription over the study period.
Comparison of Surgical Patients With and Without Granulomas
A similar analysis was performed on the subset of 600 patients with CD that underwent surgical resection during the study period ( Table 2 ). The baseline characteristics of this group were similar to the entire cohort overall. Over half of the patients (55.1%) were female, mean age at diagnosis was 27.3 years, mean age at first surgery was 37.4 years, and 95.3% of patients were non-Hispanic white. More than half (50.3%) of patients in this group were ever smokers, and 34.3% required more than one surgery during the study period. Granulomas were detected in 21.0% of surgical patients as compared with 12.8% in the entire cohort. Granulomatous CD was associated with female gender (P ¼ .0009), earlier age at diagnosis (34.1 years vs 38 years; P ¼ .004), and earlier age at first surgery. Again, there were no significant associations with race and the presence of granulomas. The proportion of smokers in the granuloma group was lower than in the no-granuloma group (42.1% vs 52.5%; P ¼ .04). Other associations, such as with medication use, laboratory abnormalities, quality of life scores, and health care expenditures, were similar to the overall group with the exceptions of lack of statistical significance for the mean HBI (P ¼ .11), and emergency department visits per year (P ¼ .29). The need for a repeat surgery during the study period was associated with granulomatous CD (P ¼ .0001). Because granuloma rates in surgical specimens may be affected by sampling at the time of gross dissection by pathology, we compared the mean number of blocks/cassettes taken per surgical specimen in the no-granuloma and granuloma groups (Supplementary Table 1 ). Results show no significant difference between the two groups (13.0 vs 15.7; P ¼ .256).
Multivariate Regression Analyses
To test which variables were independently associated with granulomatous CD, each variable with a statistically significant association in the univariate analyses above was entered into a multivariate logistic regression model. This was performed for the entire patient population (Table 3 ) and for the surgical subset of patients (Table 3 ). For the entire population, significant associations were seen for abnormal CRP and ESR, immunomodulator use, and biologic use. For the surgical subset, significant associations were seen for female gender, smoking (inverse relationship between smoking and granulomas), abnormal CRP and ESR, immunomodulator use, and need for repeat surgery.
Montreal Classification and Delta Lémann Index
The anatomic distribution and behavior of CD was characterized according to the Montreal classification ( Figure 1A and 1B) , and no significant differences were noted with respect to disease location between the two groups. However, patients with granulomatous CD were more likely to have penetrating complications (P ¼ .04) and perianal involvement (P ¼ .037). A worsening disease trajectory over 5 years as assessed by DLI was associated with the presence of granulomas ( Figure 1C ). The patients classified as having improving or stable bowel damage were less likely to have granulomatous CD. Granulomatous patients with CD were overrepresented among the group with worsening bowel damage (P values for all comparisons <.001).
Biologic Drug Exposure and Granulomas in Surgical Patients
Because anti-TNF drugs are believed to induce apoptosis of immune cells that contribute to granuloma formation, we examined the relationship between anti-TNF biologic exposure at the time of surgery, and the presence of residual granulomas on surgical specimen (Figure 2) . Of the 600 patients in the surgical group, information on biologic exposure at the time of surgery was available in 378. These patients were included in this analysis. Of these, 90 (23.8%) were taking an anti-TNF drug at the time of surgery. The rates of granuloma detection on surgical resection material were not significantly different between patients on no anti-TNF compared with any anti-TNF (29.9% vs 27.8%; P ¼ .705). However, patients on infliximab at the time of surgery were significantly less likely to have granulomas detected on histology compared with patients not receiving anti-TNF therapy (8.7% vs 29.9%; P ¼ .03). No significant differences in granuloma rates were observed in the patients on either adalimumab (P ¼ .683) or certolizumab (P ¼ .399). In surgical specimens, granulomas can be found in different layers of the bowel wall (serosa, mucosa, and lamina propria). We hypothesized that biologic therapy may affect the distribution of granulomas within the bowel wall. The histologic distribution of granulomas was examined in biologic naive patients, and no significant difference was found between the two groups.
Association of Granuloma and Need for Repeat Bowel Surgery During the Observation Period
A Kaplan-Meier analysis was performed to determine the relationship between granulomas on surgical specimen and the need for repeat surgical resection during the 6-year observation period (Figure 3 ). The presence of granulomatous CD was associated with increased rates of repeat surgical resection, seen in 50% of these patients (62 of 126; log-rank P < .001).
Discussion
The noncaseating epithelioid granuloma in the bowel wall and or associated lymph nodes is a distinctive histologic feature of CD that is found in only a subset of patients. In this analysis of a large, prospective, multiyear observational cohort, we characterized the relationship of the epithelioid granuloma with disease severity in CD. We found that the presence of granulomas, either on endoscopic biopsy or surgical resection specimen, correlated with multiple markers of disease activity and severity over a multiyear time period. These markers of CD severity included medication requirement, biochemical markers of inflammation, quality-of-life indices, patterns of health care use, aggressive disease phenotypes, and quantification of bowel damage. The data support the concept that the granuloma can be used as a biomarker of disease severity, and that more aggressive therapy may be considered in these patients with CD.
The overall percentage of patients in whom granulomas were found in this study was 12.8%, or 187 patients, which is significantly lower than what has been reported historically. Previous studies have reported granuloma rates ranging from 9% 16 to 66% 17 with most in the range of 20%-25%. [18] [19] [20] [21] Potential reasons for the lower rate of granulomas in this study include possible effects of medications, specifically anti-TNF biologic agents. Of note, data from most studies reporting granuloma rates over 20%-30% were derived from studies before 1998, when infliximab became the first biologic drug approved by the Food and Drug Administration for treatment of CD. Other possibilities for the lower rate of granulomas in this study include ethnic and racial variations in granuloma rates. It should be noted that the population in this study was predominantly nonHispanic white, whereas some other studies showing higher granuloma rates have been performed in Asia or the Middle East. 22, 23 Finally, this study included granulomas found in both endoscopic biopsies and surgical specimens. The rate in the surgical group was higher (21%), as would be expected, because of increased tissue sampling, but the higher granuloma rate could also be attributed to a greater disease severity in this group.
In this study, patterns of medication use and laboratory values in granuloma patients strongly point to a more aggressive disease phenotype. Patients with CD with granulomas were more likely to use steroids, narcotics, immunomodulators, and biologic medications. Likewise, they were more likely to have elevated inflammatory biomarkers, to have clinically active disease, worse quality of life, and higher health care use. To our knowledge, no previous studies have linked this wide range of clinical outcomes to granulomas in a large CD patient cohort followed over multiple years. [16] [17] [18] 22 An interesting result noted in the surgical group was the inverse relationship between granulomas and smoking. Although this seems surprising given that smoking itself is associated with more severe disease activity, there is evidence in the literature that smoking has a negative association with other granulomatous diseases including sarcoidosis. 24 In addition, these findings are in agreement with previous studies showing that CD granulomas are less frequent in smokers. 22 Figure 2. Granuloma rates in surgical patients according to anti-TNF exposure. Rates of granuloma in surgical patients noted in surgical specimens stratified by anti-TNF exposure at the time of surgery. *P < .05; NS, not significant. Disease location and behavior was also analyzed in the patient population according to the Montreal classification, 3 revealing that patients with granulomas are more likely to have penetrating complications and perianal disease. This is in line with previous smaller studies, [25] [26] [27] and adds to the evidence that the granuloma is associated with a more aggressive phenotype of CD.
The Lémann index is a recently developed measure of structural bowel damage, 14 and the change in Lémann index over time (DLI) has been shown to correlate with other markers of disease severity. 15 The authors examined DLI in the cohort of patients and found that granulomas were highly associated with worsening bowel damage over time. This also supports the association between granulomas and aggressive disease behavior.
We were also interested in whether the use of anti-TNF agents would impact granuloma rates in the patient population. The mechanism of action of anti-TNF monoclonal antibodies includes induction of apoptosis of immune cells via binding of membrane bound TNF receptors, and for, infliximab and adalimumab, fixation of complement. 11 Interestingly, in patients with tuberculosis, infliximab has been associated with a higher reactivation rate than etanercept, an anti-TNF agent that interacts preferentially with soluble TNF and lacks the ability to induce antibody-dependent cytotoxicity in effector cells. It has been postulated that reactivation of tuberculosis is caused by the dissolution of infectious granulomas by the previously mentioned actions of infliximab. Of note, data from this study show that patients with CD who were taking infliximab at the time of surgery are significantly less likely to have granulomas on surgical resection specimen. Therefore, the data lend indirect support to the idea that infliximab acts to dissolve granulomas. This also suggests that patients with granulomatous CD may respond better to treatment with infliximab, although this hypothesis cannot be directly tested using data from this study.
Limitations of this study include observational design, which limits the ability to elucidate cause-effect relationships between variables. Although the presence of the granuloma is associated with a more aggressive disease phenotype, the causal relationship between the granuloma and disease activity remains unclear. Although the observational design comes with certain limitations, it also provides a more accurate reflection of real world patients with CD potentially making our finding more generalizable. Other important limitations of the study are that it was conducted in a single tertiary referral center with a predominantly non-Hispanic white population.
Further studies are required to explore the relationship between the granuloma and disease severity in CD, but the authors believe that the data provide strong evidence that the presence or absence of granulomas should be considered when determining prognosis. Future work should be directed at constructing prognostic models for patients with CD, which include histopathologic biomarkers including the granuloma, to guide and personalize therapy. Repeat surgical-free survival analysis. Cumulative probability of repeat surgical resection according to granuloma status. The x-axis is years after first surgical resection.
